, Tracking Stock Market Picks
Enter Symbol:
Cleveland Biolabs, Inc. (CBLI) [hlAlert]

Mkt Outperform
up 172.99 %

Cleveland Biolabs, Inc. (CBLI) rated Mkt Outperform with price target $4 by Burrill Institutional Research

Posted on: Tuesday,  Dec 4, 2012  8:25 AM ET by Burrill Institutional Research

Burrill Institutional Research rated Mkt Outperform Cleveland Biolabs, Inc. (NASDAQ: CBLI) on 12/04/2012, when the stock price was $1.37.
Since then, Cleveland Biolabs, Inc. has gained 172.99% as of 08/27/2015's recent price of $3.74.
If you would have followed this Burrill Institutional Research's recommendation on CBLI, you would have gained 172.99% of your investment in 996 days.

Cleveland BioLabs, Inc. (CBLI) is a development-stage biotechnology company. The Company is focused on developing cancer treatment, tissue protection and biodefense drugs. The Company?s pipeline includes products from two primary families of compounds: protectans and curaxins. CBLI is developing protectans as drug candidates that protect healthy tissues from acute stresses such as radiation, chemotherapy and ischemia (pathologies that develop as a result of blocking blood flow to a part of the body). Curaxins are being developed as anticancer agents that could act as mono-therapy drugs or in combination with other existing anticancer therapies.

Burrill Institutional Research
Stock Market Advice
Date/Time (ET)SymbolRatingTermPrice (*)Target
12/4/2012 8:25 AM Buy
1.37 4.00
as of 12/31/2012
1 Week up  0.75 %
1 Month down  -2.91 %
3 Months   
1 YTD down  -2.91 %

(*) Stock Price at the time of the recommendation.
RSS Feed | |  Facebook |  Twitter |  Google Plus
Home | Terms of Use | Advertise | FAQ | Support Page | Contact Us | About Us | Privacy Policy